(Q44718649)

5 December 2017

Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation (English)

1 reference

5 December 2017

Joshua A Cohn

1

1 reference

5 December 2017

Chihsiung E Wang

2

1 reference

5 December 2017

Justin C Lakeman

3

1 reference

5 December 2017

Jonathan C Silverstein

4

1 reference

5 December 2017

Charles B Brendler

5

1 reference

5 December 2017

Kristian R Novakovic

6

1 reference

5 December 2017

Michael S McGuire

7

1 reference

5 December 2017

Brian T Helfand

8

1 reference

5 December 2017

2 August 2013

1 reference

5 December 2017

1 reference

5 December 2017

32

1 reference

5 December 2017

41.e23-30

1 reference

5 December 2017

1

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Quality of life and satisfaction with outcome among prostate-cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

PSA screening: determinants of primary-care physician practice patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Primary care physicians' use of an informed decision-making process for prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Influence of publication of US and European prostate cancer screening trials on PSA testing practices.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

2008 US Preventive Services Task Force recommendations and prostate cancer screening rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Prostate specific antigen testing among the elderly--when to stop?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.04.013

10.1016/J.UROLONC.2013.04.013

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference